title: Course of viral hepatitis B and combined B and C hepatitis in children treated for neoplastic diseases.
abstract: BACKGROUND
  Viral hepatitis C in children is milder than in adults. Patients with tumors, because of immune deficits, seem to be at risk of rapid liver disease progression. Little is known about the course of HCV and dual HBV-HCV infections in such patients.
  
  
  METHODS
  The study assessed clinical courses of HCV and dual HBV-HCV infections in 249 children with tumors aged 1-18 years, divided into four groups: with HCV infection - 53, HBV-HCV infection - 53, HBV only - 33 and infection-free - 110.
  
  
  RESULTS
  Hepatitis C was often chronic - in 83.3% of patients with HCV and 77.3% of those with dual infection. Over 80% had no jaundice. Mean AlAT activity was the highest in the HCV group (149.2I202.7 IU/l), lower in the dual infection group (123.3I148.1 IU/l; p<0.02), and the lowest in HBV (92.7I152.9 IU/l). Transaminasemia course in patients with HCV and dual HBV-HCV infections was most frequently fluctuating (50.9% and 45.3%, respectively). 52.8% of children with HCV demonstrated no advanced inflammatory lesions with invasion of the lamina limitans, no marked fibrosis, and minimum changes in descriptive classification. In 92.3% of children with dual infections, inflammatory activity was mild or mean, with no fibrosis in 61.5%, and persistent chronic inflammation predominant in descriptive classification (46.1%).
  
  
  CONCLUSIONS
  HCV and HBV-HCV infections in children with neoplastic diseases tend to take chronic forms, but their clinical course is mild with signs of severe inflammatory activity or hepatic stroma remodeling observed on histopathology.
authors.affiliation: Department and Clinic of Paediatrics, Haematology and Oncology, Medical University, Bydgoszcz, Poland.
authors.forename: Sylwia
authors.initials: S
authors.lastname: Kołtan
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kołtan
authors.forename: Violetta
authors.initials: V
authors.lastname: Swiatkiewicz
authors.forename: Jan
authors.initials: J
authors.lastname: Styczyński
authors.forename: Robert
authors.initials: R
authors.lastname: Debski
authors.forename: Anna
authors.initials: A
authors.lastname: Balcar-Boroń
mesh_terms: D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001663:Bilirubin / Q000097:blood; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000097:blood / Q000150:complications* / Q000473:pathology; D019694:Hepatitis B, Chronic / Q000453:epidemiology; D006526:Hepatitis C / Q000097:blood / Q000150:complications* / Q000473:pathology; D019698:Hepatitis C, Chronic / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007223:Infant; D007938:Leukemia / Q000097:blood / Q000150:complications / Q000188:drug therapy; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000097:blood / Q000209:etiology / Q000473:pathology; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D012720:Severity of Illness Index
chemical_list: D000970:Antineoplastic Agents; D000410:Alanine Transaminase; D001663:Bilirubin